Fujifilm, Helio partner on blood assay for detecting liver cancer

LabPulse.com staff writers
May 12, 2021
2019 08 01 23 27 1210 Fujifilm Rsna 2018 400

Fujifilm Medical Systems and Helio Health announced they are collaborating on the development of a blood-based assay for the early detection of liver cancer.

Helio Health's DNA methylation and biomarker-based blood test technology, called the HelioLiver test, will leverage Fujifilm's 510(k)-cleared, microfluidic-based clinical immunoanalyzer for IVD use, according to the companies.

The collaboration will provide expanded monitoring and treatment options for patients at high risk of developing liver cancer, the companies stated.

Latest in Liver Cancer
Artificial Intelligence Lung Color Social
Machine-learning model predicts lung and liver cancer through genome sequence changes
March 15, 2024
Visit our Molecular Diagnostics Community
Sponsored
Visit our Molecular Diagnostics Community
April 5, 2024
Liver Cancer Social
Gene mutations linked to drug-resistant liver cancer
June 26, 2023
Liver Anatomy Social
Johns Hopkins cell-free DNA blood test detects 80% of liver cancers in study
November 18, 2022
Related Stories
Liver Anatomy Social
Liver Cancer
LAMH receives Chinese approval for blood test designed to accelerate liver cancer diagnosis
Pathology Digital Workstation Microscope Social
Pathology, histology
Fujifilm to debut acquired pathology solution at HIMSS 2023
2019 04 26 21 48 5250 Money Hundred Bills 400
CPT Code
Helio Genomics obtains CPT code for liver cancer test
Visit our Molecular Diagnostics Community
Sponsor Content
Visit our Molecular Diagnostics Community
More in Liver Cancer
Machine-learning model predicts lung and liver cancer through genome sequence changes
By LabPulse.com staff writers
Researchers have developed a machine-learning approach that may potentially predict early-stage lung or liver cancer by detecting repetitive sequences in the genome.
March 15, 2024
Artificial Intelligence Lung Color Social
LAMH receives Chinese approval for blood test designed to accelerate liver cancer diagnosis
By Nick Paul Taylor
The test was based on the multianalyte blood test HelioLiver, developed by Helio Genomics, and adapted for the genetics of the Asia-Pacific population, resulting in a product that could help address a major healthcare challenge in China.
July 5, 2023
Liver Anatomy Social
Gene mutations linked to drug-resistant liver cancer
By Elissa Wolfson
Certain gene mutations could help physicians predict which hepatocellular carcinoma patients are most likely to develop drug resistance to lenvatinib.
June 26, 2023
Liver Cancer Social
Johns Hopkins cell-free DNA blood test detects 80% of liver cancers in study
By Leo O'Connor
The researchers believe there is potential to leverage the technology to develop a commercial blood test to detect hepatocellular cancer with higher accuracy than current tests.
November 18, 2022
Liver Anatomy Social
Delfi Diagnostics to present proof-of-concept data for liver cancer detection platform
By LabPulse.com staff writers
Delfi Diagnostics will present data on the efficacy of their liver cancer detection platform at the American Association for the Study of Liver Disease annual meeting.
October 28, 2022
Liver Digital Tablet
Biomarker assay may speed primary liver cancer detection
By Joseph Constance
While EVs are released by normal cells, they are released to a greater extent by tumor cells and cells within a tumor microenvironment. Investigators at the University of California at Los Angeles (UCLA) and collaborators elsewhere have developed a streamlined surface protein assay (HCC EV SPA) capable of analyzing and quantifying eight subpopulations of HCC EVs.
August 15, 2022
2021 06 08 21 44 7484 Cancer Cell Yellow 400
Helio Genomics obtains CPT code for liver cancer test
By LabPulse.com staff writers
When it takes effect on October 1, the new CPT PLA code will provide a reimbursement pathway to enable increased access to HelioLiver, according to the vendors.
July 4, 2022
2019 04 26 21 48 5250 Money Hundred Bills 400
Helio publishes study of HelioLiver cancer test
By LabPulse.com staff writers
In a prospective phase II study, HelioLiver demonstrated high specificity (91%) and high sensitivity (76%) in detecting early-stage (stage I and II) HCC. In addition, it significantly outperformed other clinically available detection tools such as serum alpha-fetoprotein (AFP) (57%), GALAD (gender, age, Lens culinaris agglutinin-reactive AFP, and des-gamma-carboxy prothrombin [DCP]) scores (65%), and ultrasound (47%) (Hepatology Communications, March 3, 2022).
March 9, 2022
2019 08 20 22 16 4501 Liver Anatomy 400
Liver cancer diagnostic test offers promise of early detection
By LabPulse.com staff writers
The platform is called EV Click Chips, and the hope is that it will enable more effective purification of extracellular vesicles in blood from people with hepatocellular carcinoma. Researchers from the University of California, Los Angeles (UCLA) Jonsson Comprehensive Cancer Center have received a $2.97 million grant from the U.S. National Cancer Institute (NCI) to develop the technology further.
August 4, 2020
2020 01 22 00 12 9591 Liver Cancer 400
Blood test identifies patients at risk for liver cancer
By LabPulse.com staff writers
The test analyzes patients' previous viral exposure to accurately predict whether they might develop hepatocellular carcinoma (HCC). It was created by researchers from the U.S. National Institutes of Health and several academic centers to help improve liver cancer screening and early detection.
June 11, 2020
2019 08 20 22 16 4501 Liver Anatomy 400
Page 1 of 1